Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503

Microvascular Research

Volumn 81, Issue 1, 2011, Pages 44-51

  Rice, Lori ^a   Pampo, Christine ^a   Lepler, Sharon ^a   Rojiani, Amyn M ^b   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Combretastatin; Endothelial cells; Magnetic resonance imaging; OXi4503; Tubulin binding agents; Vascular disrupting agents; Viable rim

Indexed keywords

COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; TUMOR BLOOD FLOW; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; CELL SURVIVAL; CELLS, CULTURED; DIPHOSPHATES; ENDOTHELIAL CELLS; FEMALE; FREE RADICALS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C3H; MICROTUBULES; NECROSIS; NEOVASCULARIZATION, PHYSIOLOGIC; REGIONAL BLOOD FLOW; SARCOMA, EXPERIMENTAL; STILBENES; TUBULIN MODULATORS; TUMOR STEM CELL ASSAY;

MUS;

EID: 78650826753     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2010.10.003     Document Type: Article

References (59)

1. Ahmed B., et al. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int. J. Cancer 1993, 105:20-25.
2. Azam F., et al. Mechanisms of resistance to antiangiogenesis therapy. Eur. J. Cancer 2010, 46(8):1323-1332.
3. Beerepoot L.V., et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J. Clin. Oncol. 2006, 24(10):1491-1498.
4. Bijman M.N.A., et al. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mo. Cancer 2006, 5(9):2348-2357.
5. Bloemendal H.J., et al. New strategies in anti-vascular cancer therapy. Eur. J. Clin. Invest. 1999, 29(9):802-809.
6. Calligaris D., et al. Microtubule targeting agents: from biophysics to proteomics. Cell. Mol. Life Sci. 2010, 67(7):1089-1104.
7. Chan L.S., et al. Selective targeting of the tumour vasculature. ANZ J. Surg. 2008, 78(11):955-967.
8. Chan L.S., et al. Alterations in vascular architecture and permeability following OXi4503 treatment. Anticancer Drugs 2008, 19(1):17-22.
9. Chan L.S., et al. Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis. Anticancer Res. 2007, 4B:2317-2323.
10. Chaplin D.J., et al. Current development status of small-molecule vascular disrupting agents. Curr. Opin. Investig. Drugs 2006, 6:22-528.
11. Davis P.D., et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 2002, 62(24):7247-7253.
12. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br. J. Cancer 1982, 45(136):139.
13. Denekamp J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eu. J. Clin. Invest. 1999, 29(9):733-736.
14. Denekamp J., Hobson B. Endothelial-cell proliferation in experimental tumours. Br. J. Cancer 1982, 46:711-720.
15. Dowlati A., et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002, 62(12):3408-3416.
16. Folkes L.K., et al. Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem. Res. Toxicol. 2007, 20(12):1885-1894.
17. Gaya A.M., Rustin G.J. Vascular disrupting agents: a new class of drug in cancer therapy. Clin. Oncol. R Coll Radiol. 2005, 17(4):277-290.
18. Galbraith S.M., et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 2001, 21(1A):93-102.
19. Grosios K., et al. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 1999, 81(8):1318-1327.
20. Hamel E., Lin C.M. Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin. Biochem. Pharmacol. 1983, 32(24):3864-3867.
21. Hansen S., et al. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin. Cancer Res. 2000, 6:139-146.
22. Hill S.A., et al. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res. 2002, 22(3):1453-1458.
23. Hobson B., Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br. J. Cancer 1984, 49(405):413.
24. Holwell S.E., et al. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res. 2002, 22(2A):707-711.
25. Horsman M.R., Siemann D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006, 66(24):11520-11539.
26. Hua J., et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 2003, 23(2B):1433-1440.
27. Kallman R.F., et al. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J. Natl Cancer Inst. 1967, 39(3):539-549.
28. Kanthou C., Tozer G.M. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int. J. Exp. Pathol. 2009, 90(3):284-294.
29. Kirwan I.G., et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin. Cancer Res. 2004, 10(4):1446-1453.
30. Ljungkvist A.S., et al. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54(1):215-228.
31. Lin C.M., et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. 1988, 34(2):200-208.
32. Lippert J.W. Vascular disrupting agents. Bioorg. Med. Chem. 2007, 15(2):605-615. Epub 2006.
33. Madlambayan G.J., et al. Leukemia regression by vascular disruption and anti-angiogenic therapy. Blood 2010, Epub May 14 ahead of print.
34. Malcontenti-Wilson C., et al. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin. Cancer Res. 2001, 7(4):1052-1060.
35. McKeage M.J., Baguley B.C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010, 116(8):1859-1871.
36. Rojiani A.M., Rojiani M.V. Morphologic manifestations of vascular-disrupting agents in preclinical models. Vascular-targeted therapies in oncology 2006, 81-84. Wiley, London. D.W. Siemann (Ed.).
37. Rojiani A.M., et al. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol. 2002, 41(1):98-105.
38. Rossi A., et al. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer. Curr. Med. Chem. 2009, 16(30):3919-3930.
39. Rustin G.J., et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 2003, 21(15):2815-2822.
40. Salmon H.W., Siemann D.W. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin. Cancer Res. 2006, 12(13):4090-4094.
41. Salmon H.W., et al. Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique. Eur. J. Cancer 2006, 42(17):3073-3078.
42. Salmon B.A., Siemann D.W. Characterizing the tumor response to CA4P treatment. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68:211-217.
43. Salmon B.A., et al. Monitoring the treatment efficacy of the vascular disrupting agent CA4P. Eur. J. Cancer 2007, 43:1622-1629.
44. Sheng Y., et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int. J. Cancer 2004, 111(4):604-610.
45. Shnyder S.D., et al. Anticancer Res. 2003, 23(2B):1619-1623.
46. Siemann D.W., Horsman M.R. Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Rev. Anticancer Ther. 2004, 4(2):321-327.
47. Siemann D.W., Horsman M.R. Vascular targeted therapies in oncology. Cell Tissue Res. 2009, 335(1):241-248.
48. Siemann D.W., et al. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. 2005, 11(2 Pt 1):416-420.
49. Siemann D.W., et al. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer 2002, 99(1):1-6.
50. Siemann D.W., Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53:164-171.
51. Siemann D.W., Rojiani A.M. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large advanced tumors. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:846-853.
52. Siemann D.W., et al. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin. Investig. Drugs 2009, 18(2):189-197.
53. Siemann D.W., et al. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004, 100(12):2491-2499.
54. Siemann D.W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat. Rev. 2010, epub Jun. 4.
55. Schwartz E.L. Antivascular actions of microtubule-binding drugs. Clin. Cancer Res. 2009, 15(8):2594-2601.
56. Sriram M., et al. Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy. Bioorg. Med. Chem. 2008, 16(17):8161-8171.
57. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 2004, 10(2):415-427.
58. Vincent L. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J. Clin. Invest. 2005, 115(11):2992-3006.
59. Wankhede M., et al. In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503 2009.